WallStreetZenWallStreetZen

NASDAQ: UNCY
Unicycive Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for UNCY

Based on 4 analysts offering 12 month price targets for Unicycive Therapeutics Inc.
Min Forecast
$3.00+188.46%
Avg Forecast
$5.63+440.87%
Max Forecast
$9.00+765.38%

Should I buy or sell UNCY stock?

Based on 4 analysts offering ratings for Unicycive Therapeutics Inc.
Strong Buy
Strong Buy
1 analysts 25%
Buy
3 analysts 75%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their UNCY stock forecasts and price targets.

UNCY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-14
lockedlocked$00.00+00.00%2024-04-15
lockedlocked$00.00+00.00%2024-04-04
lockedlocked$00.00+00.00%2024-02-14

1 of 1

Forecast return on equity

Is UNCY forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is UNCY forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

UNCY revenue forecast

What is UNCY's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$30.3M
Avg 2 year Forecast
$264.5M
Avg 3 year Forecast
$517.8M

UNCY vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
UNCY$1.04$5.63+440.87%Strong Buy
QNCX$0.91N/AN/A
ACHL$0.95$2.83+198.84%Hold
OKYO$1.52$7.00+360.53%Buy
FBIO$1.93$12.50+547.67%Strong Buy

Unicycive Therapeutics Stock Forecast FAQ

Is Unicycive Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: UNCY) stock is to Strong Buy UNCY stock.

Out of 4 analysts, 1 (25%) are recommending UNCY as a Strong Buy, 3 (75%) are recommending UNCY as a Buy, 0 (0%) are recommending UNCY as a Hold, 0 (0%) are recommending UNCY as a Sell, and 0 (0%) are recommending UNCY as a Strong Sell.

If you're new to stock investing, here's how to buy Unicycive Therapeutics stock.

What is UNCY's revenue growth forecast for 2025-2027?

(NASDAQ: UNCY) Unicycive Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.

Unicycive Therapeutics's revenue in 2024 is $0.On average, 3 Wall Street analysts forecast UNCY's revenue for 2025 to be $1,139,405,676, with the lowest UNCY revenue forecast at $75,965,393, and the highest UNCY revenue forecast at $3,186,597,793. On average, 3 Wall Street analysts forecast UNCY's revenue for 2026 to be $9,947,367,308, with the lowest UNCY revenue forecast at $741,226,677, and the highest UNCY revenue forecast at $18,714,939,420.

In 2027, UNCY is forecast to generate $19,470,832,683 in revenue, with the lowest revenue forecast at $1,438,453,598 and the highest revenue forecast at $42,811,349,985.

What is UNCY's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: UNCY) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is UNCY's Price Target?

According to 4 Wall Street analysts that have issued a 1 year UNCY price target, the average UNCY price target is $5.63, with the highest UNCY stock price forecast at $9.00 and the lowest UNCY stock price forecast at $3.00.

On average, Wall Street analysts predict that Unicycive Therapeutics's share price could reach $5.63 by May 14, 2025. The average Unicycive Therapeutics stock price prediction forecasts a potential upside of 440.87% from the current UNCY share price of $1.04.

What is UNCY's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: UNCY) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.